A new study reveals disappointing results on the potential of GLP-1 drugs like Ozempic to treat Parkinson's disease. Despite ...

People with type 2 diabetes who used semaglutide (Ozempic) versus other drugs had a lower risk of Alzheimer's disease and ...

WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's disease have taken an hit.

A rigorous study that randomly assigned Parkinson’s patients to take exenatide, a relative of Ozempic, showed absolutely no benefit or slowing of the course of the degenerative disease after 96 ...

GLP-1 agonists like Wegovy, Ozempic, and Mounjaro might benefit heart and brain health—but research suggests they might also ...

Canadian endocrinologist Daniel J. Drucker — a diabetes treatment pioneer whose work paved the way for Ozempic — is sharing what's next for these obesity and diabetes drugs.

They were designed to treat diabetes, then prescribed for weight loss, and now—as researchers are finding—they might hold the secret to staving off Alzheimer’s, too.

Hungarian-born scientist Bence Ölveczky fears his lab's groundbreaking work on brain function and motor skills will end as federal funding disappears.

A new study reveals disappointing results on the potential of GLP-1 drugs like Ozempic to treat Parkinson's disease. Despite earlier hopes, a rigorous 96-week trial with 194 participants found no ...

GLP-1 drugs like Ozempic do not slow Parkinson's disease, study finds The trial showed no benefit in symptoms or brain scans Experts say more research is needed before using these drugs for brain ...